Stoke Therapeutics (STOK) Income from Continuing Operations (2018 - 2026)

Stoke Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 50003000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 144.3% year-over-year to 50003000.0; the TTM figure through Mar 2026 stood at 169657000.0 (down 438.83% YoY), while the FY2025 annual figure was 6834000.0, up 92.3% from the prior year.
• Income from Continuing Operations was 50003000.0 for Q1 2026 at Stoke Therapeutics, up from 57824000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 112879000.0 in Q1 2025 to a low of 57824000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 20709352.94 across 5 years, with a median of 25697000.0 in 2022.
• Biggest YoY gain for Income from Continuing Operations was 527.99% in 2025; the steepest drop was 441.27% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 25697000.0 in 2022, then dropped by 5.07% to 26999000.0 in 2023, then surged by 60.43% to 10683000.0 in 2024, then sank by 441.27% to 57824000.0 in 2025, then rose by 13.53% to 50003000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 50003000.0 (Q1 2026), 57824000.0 (Q4 2025), and 38347000.0 (Q3 2025), per Business Quant data.